Mersana Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning. Thanks for joining us for another session at the 42nd J.P. Morgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. I'm joined by my associate, Sean Kim, who's on the -- who's in the audience. On stage, we have Mersana Therapeutics' CEO, Marty Huber. I'll pass the mic to Marty for a short presentation, followed by a live audience Q&A. (Conference Instructions)
Marty, I will turn the stage to you.
Good morning, Brian. I would like to thank J.P. Morgan for the opportunity to share the Mersana story. Please be aware that this presentation will contain forward-looking statements that are subject to certain risks and uncertainties, including those you see on this slide. For additional details about these risks, please refer to our most recent 10-Q filings available at sec.gov.
As we all know, 2023 was a banner year for ADCs, one filled with new product approvals and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |